Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Non-product branded APS, pre-NOC teasers
  4. 99 - Does PAAB have specific rules regarding Pre-NOC communications
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

99 - Does PAAB have specific rules regarding Pre-NOC communications

Scheduled Pinned Locked Moved Non-product branded APS, pre-NOC teasers
1 Posts 1 Posters 465 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by
    #1

    Are you allowed to send out a pre-NOC communication that focuses on the disease, patients current unmet need and that a new option for treatment is coming soon?

    PAAB has had a guidance on pre-NOC review of communications since 2003. It is posted on the PAAB web-site www.paab.ca. This type of message usually falls into "editorial" advertising and you should refer to the second paragraph of 7.6.1. Federal law and PAAB code section 3.1 prohibits advertising of a health product prior to Health Canada approval for marketing. Therefore, you cannot point to a "new option" or any other wording that depicts a specific product. You can speak to the disease and to some degree "patient's unmet needs" but not if it is disparaging to current therapy or points at a specific alternative. For new projects, I suggest calling the PAAB office and ask for a verbal opinion at no charge regarding the need for PAAB review.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups